Briumvi is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Please provide your email address to receive an email when new articles are posted on . Study examined 41 individuals with RRMS and 20 healthy controls required to wear accelerometer for 1 week.

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

Key updates in disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) forum are reported ...

The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...

HOUSTON--(BUSINESS WIRE)--Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine ...